FDA Approval of Ameluz Seen as Boon to Skin Cancer Armamentarium—Medscape

Read article—Shane Chapman, a professor of dermatology, is featured discussing the FDA's approval of Biofrontera's Ameluz topical gel, the first photodynamic therapy drug approved in the U.S. for skin cancer. "It's going to be a great FDA-approved option going forward," particularly for patients who cannot or prefer not to undergo surgery, said Chapman, who was an investigator on the drug's phase 3 trial.